Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed. The Company plans to initiate the clinical trial in the second half of 2022.
https://finance.yahoo.com/news/indaptus-therapeutics-announces-fda-clearance-110000411.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.